Astha is a Senior Data Analyst Associate at RA Capital Management. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Sophie led the cell therapy program, working with teams across the Trust to build capabilities to deliver industry and academically sponsored complex cell therapy trials for solid tumor cancer patients. Prior to joining RA, Kyle was a Partner at Breakthrough Energy Ventures (BEV), where he led investments and served on company boards that span the utilities, energy storage, chemicals, agriculture, automotive, recycling, and consumer products sectors. 'All These Sons,' 'Peter Case: A Million Miles Away' Set 2023 Release Dan Guglielmo is IT Operations Associate at RA Capital Management. Abhishek gained experience using data analytics to track and visualize patient testing in his most recent role at Blueprint Medicines. In this role, he propelled the company to the next stage of growth and increased shareholder value by altering the course of this formerly research-based company to prioritize innovation, speed to commercialization, and culture transformation. As Director of Global Marketing, she provided global leadership for the launch of Otezla for the treatment of patients with psoriasis and psoriatic arthritis. Prior to RAVen, Cosmas was an Entrepreneur in Residence at Third Rock Ventures and was part of the teams that built Asher Bio (cell targeted biologics for oncology/autoimmune diseases) and Septerna (GPCR focused drug discovery) as well as other NewCOs in development. Joey holds a Bachelor of Science in Finance from American University and is FINRA-certified in Series 7, Series 63 and Securities Industry Essentials. Kathryn holds a BA in Geography and Peace and Conflict Studies from Colgate University, a MSc in International Development: Environment and Development from the University of Manchester (UK), and a MA and Ph.D. in Geography from Clark University (2016). Joels first role in Biotech was as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. The market worked. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in . He is also the co-founder of multiple biotechnology companies including HiFiBiO and Design Pharmaceuticals. James was most recently the founder, Chief Executive Officer, and served as a Board Director for Imara, a public company developing therapies for sickle cell disease and -thallasemia. Jeff holds a BA in Economics and Psychology from Georgetown. Her contributions involve engagement with teams across RA Capital, including the processing of CDA's. Prithviraj has a BS from Duke University and an MBA from Kellogg School of Management, Northwestern University. Peter founded and serves as a Director ofNo Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. Brians primary responsibility at RA Capital is to conduct due diligence on biotechnology companies. Analysis: Top Biotech VC Investors in 2021 Based on - Insider Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Priscilla Lee is an Associate within the TechAtlas division of RA Capital Management. Raj holds a BA from Cornell University, where he majored in Chemistry. Chris Caliri is the Chief Information Officer at RA Capital Management. Bethany is a Senior Finance Associate at RA Capital Management. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. Katherines primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. He earned his PhD in Biomedical Science & Translational Medicine from Cedars-Sinai Medical Center and completed his Postdoctoral Fellowship in Molecular Pathology & Oncology at Harvard Medical School. Jon Lundt is a Senior Associate within the TechAtlas division of RA Capital Management. Sophie was a principal investigator in the Early Phase Trials Team at GSTT and has extensive experience in the delivery of early to late phase oncology trials. Merediths primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Before her time at New Care, she was a Student Researcher at Boston Childrens Hospital Labs of Cognitive Neuroscience. Nate has a BS in Biological Sciences from University of Vermont. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. Garrett has over 20 years of experience in cell and gene therapy, including over 12 years in roles of increasing responsibility in biotech companies, including with Bluebird Bio, Audentes Therapeutics, and Ambys Medicines, and he was most recently the VP of Gene Therapy at Voyager Therapeutics. Emily has her BS in Chemical Engineering from Rensselaer Polytechnic Institute in NY. Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Lorena has dual degrees from Beijing Foreign Studies University: a Bachelor of Business Administration in Accounting and a Bachelor of Arts in English Literature. Pieter Boelhouwer is a Partner and Managing Director of Strategy and Operations at RA Capital Management. His laboratory at the Broad focused on advanced high throughput biotechnology tools including DNA synthesis, single cell analysis, synthetic biology derived biomolecule libraries, and microbiome profiling. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Maxs primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. In this role, Maryann supports start-up business infrastructure development for newcos as well as provides strategic HR guidance for founding team members. Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. Peter has a BS in Biology with minors in both Chemistry and Spanish for the Medical Professions from the University of North Carolina at Chapel Hill. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. Christys primary responsibilities at RA Capital are to work closely with the Investment Team to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. Joshs primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Emily started her career in strategy consulting at Frankel Group. The strange and special case of epinephrine | by Peter Kolchinsky | The Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Peter Kolchinsky, PhD '01, is a founder, Portfolio Manager, and Managing Director at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences. Josh holds a BS in Genetics, Genomics, and Biotechnology with a Minor in Business from Brigham Young University. Andrews primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Jaimie holds a BA in Biology Boston College, with Minors in Medical Humanities and Sociology, and a Master of Public Health from Boston University School of Public Health. Henrys primary responsibility is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. James Schneider is the Deputy General Counsel at RA Capital Management. Priscilla previously held a Senior Scientist role at Sanofi. Robert received his BS in mechanical engineering from the University of Houston. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University. He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. Shannon has a BA in Special Education and English from Bridgewater University and a MS in Elementary Education from Boston College. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. David Migl is an Analyst on the Investment Team at RA Capital Management. Matthew Feresten is a Business Systems Analyst at RA Capital Management. Alex comes to RA from Mirai Advisory, where he specialized in financial risk and data science and developed machine learning algorithms to support banks managing regulatory and operational challenges. Brian holds a BA in Politics from Princeton University and an MBA in Health Care Management from University of Pennsylvania. Toms primary responsibility is to support all aspects of trade and treasury operations. Pieter holds a BA from Trinity College and a JD from Yale Law School. Lucas holds a BA in Criminal Justice and Philosophy from John Jay College of Criminal Justice in NY, a JD, Privacy Concentration, from Northeastern University School of Law, and is admitted to practice law in MA. In this role, Gerald is responsible for evaluating new technology and novel biology to originate and support the generation of new companies in collaboration with RAVens Venture Partners and EIRs. Fuad has a BA in Biology with a Minor in Psychology and earned a PhD in Biological Chemistry, both from Washington University in St. Louis. Dan studied Network Communications & Information Services at Lincoln Technical. Kate's primary responsibility is to work with both the Legal and Compliance Teams in support of their programs. Brian has more than ten years of buy-side experience covering the healthcare sector, with a focus on biotech, pharma, and specialty pharma. Prior to joining RAVen, Maryann was Director of Business Operations and HR at Q32 Bio where she wore many hats helping to establish the companys business infrastructure including IT, contract management, facilities, administrative support, Human Resources, recruiting, internal communications and was a strong driver of company culture. He holds a BS in Biology from the College of William and Mary, where he studied the impact of ecological fragmentation on the prevalence of ticks and their bacterial pathogens. Priscilla has a B.S. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. Generali's No.3 investor Caltagirone withholds backing for 2022 accounts -sources, Musk says Tesla likely to launch full self-drive technology 'this year', Exclusive: JPMorgan employees gripe about Dimon's return-to-office edict, SpaceX rocket explosion illustrates Elon Musk's 'successful failure' formula, Cucinelli posts 33% rise in Q1 sales, confirms 2023 revenue growth forecast, Exclusive-Peter Thiel, Republican megadonor, won't fund candidates in 2024 - sources, Virginia Governor Youngkin 'humbled' by talk of possible presidential run, European Midday Briefing: Mood Brighter After -2-, Tim Cook unveils new Apple store in India, Morgan Stanley's dealmaking CEO Gorman signals more transactions to come, RA Capital Management LP (Private Equity). Elena has a BA in Molecular, Cellular, Developmental Biology from University of Colorado, Boulder and a PhD in Molecular, Cellular Biology and Biochemistry from Boston University. The 30-Year-Old CEO Conjuring Drug Companies From Thin Air - Forbes Since 2002, he has been working in start-up pharma companies, including co-founding Thesan Pharmaceuticals and NeoKera, where he assumed responsibilities for all development activities, including regulatory affairs. Tom Thomas is an Associate with the TechAtlas division of RA Capital Management. Peter Kolchinsky, Ph.D. Board Member Peter Kolchinsky, Ph.D., has more than 18 years of experience in healthcare investing and is the founder of and a managing partner at RA Capital. Tom is a Senior Operations Analyst at RA Capital Management. In this role, he will work to evaluate and incubate early-stage therapeutic programs. Emily Gransky is VP of Recruiting at RA Ventures (RAVen). Peter Kolchinsky - Biography - MarketScreener.com Laura Tadvalkar is a Managing Director on the Venture Team at RA Capital Management. Angela's primary responsibilities at RAVen are to lead development and oversee implementation of best practices in clinical strategies in RA's newcos and portfolio companies. "Too old," said a man in his 70s. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group. She works with RAs newcos to develop optimal pitch decks and public messaging, authors articles, and runs the firms internal and external business courses. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. She previously worked as a Finance Associate at the MFA Companies. Prior to RA Capital, Nate worked as an Investment Analyst at Wolfram Ventures. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Dan Marks is a Principal on the Venture Team at RA Capital Management. Prior to Catamaran, Mark served as Vice President, Legal Affairs at Rubius Therapeutics where he was responsible for leading internal legal activities in support of Rubius IPO and its growth to a clinical-stage company. Previously, Derek covered solid tumor oncology landscapes. Patrick received his PhD in Natural Sciences, specifically Biochemistry and Molecular Biology, from the Leopold-Franzens University, Innsbruck, Austria. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development. Prior to moving to BMS, he spent five years at Hoffmann La-Roche as a research scientist. Fuads primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. He holds Microsoft 365 and Microsoft certifications as Messaging Administrator Associate, Teams Administrator Associate, Teamwork Administrator Associate, and Azure Administrator Associate. Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). Jake Simson is a Partner at RA Capital Management. Prior to RA, Christy was a Senior Scientist in Oncology Target Discovery at Pfizer. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. He is a co-author on over 140 publications and is a co-inventor on 40 issued U.S. patents. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Peterconducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. Peter Kolchinsky Phone Number, Address, Age, Contact Info, Public Matthew Hammond is a Principal on the Investment Team at RA Capital Management. This is a re-publication of an op-ed that first appeared in the Wall Street Journal on September 30, 2018 and is now included in The Biotech Social Contract series of . During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Patrick was instrumental to building Constellations discovery platform, establishing a portfolio of competitive clinical candidates and drove the maturation of the companys development efforts, leading to one PhIII and two PhII assets and three additional clinical candidates. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Katherine has a as a BA in Mathematics and a Minor in Chemistry from Boston College and a Master of Science in Medical Science from Boston University School of Medicine. Monica holds a BSc in Neuroscience and Pharmacology from the University of Toronto and a PhD in Cancer Biology from MIT. Peter Pan & Wendy review - Jude Law has fun in a so-so reinvention Natalie Camacho is an Executive Assistant at RA Ventures (RAVen). He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Jessica Sagers is Head of Engagement at RA Capital Management. Ramin completed his internal medicine residency at Brigham & Womens Hospital in Boston and trained in cardiovascular medicine at UCSF. From 1997-2000, Scott served as General Manager of Biopharmaceuticals, Corporate Vice President of Business Development, and a member of the Board ofDirectors of Altus Pharmaceuticals, Inc (Nasdaq: ALTU). Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Jesse has more than a decade of discovery research and management experience, from early discovery through preclinical development. Most recently, David served as Director of Operations at Corbin Capital Partners, LP. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. Jenna Hebert is an Associate within the TechAtlas division of RA Capital Management. She has a BA in Communication Studies from University of Minnesota, Twin Cities. Nate Davis is an Analyst on the Investment Team at RA Capital Management. Ben Dake is a Venture Associate at RA Capital Management. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Candice Galvez is an Executive Assistant at RA Capital Management. Prior to joining RA Capital, Alonso was Chief Technology and Innovation Officer at Ra Pharmaceuticals until it was acquired by UCB in 2020. Tom has more than nine years of operations experience. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. He works closely with RA's Investment Team on novel drug discovery platforms with emphasis on computational chemistry and machine learning. Sadik Kassim is a scientist and executive with extensive experience in the biotechnology industry with a specific focus on cell and gene therapy bioprocessing and translational research. Cristina holds a Bachelor of Arts in Biochemistry from Mount Holyoke College and a PhD in Cell Biology and Epigenetics from Cornell University and The Rockefeller University. James is admitted to practice law in the Commonwealth of Massachusetts. She has twenty years of oncology experience with a strong focus on skin cancers, especially malignant melanoma. Brendan is a Tax Director at RA Capital Management.